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Pritumumab is a natural human IgG1 kappa antibody that
has been derived from a B cell isolated from regional
draining lymph node of a cervical carcinoma patient.
Specificity analysis of the antibody with human tissues
showed the target antigen, altered tumor-associated
vimentin, to be highly restricted to various epithelial
cancers and not normal cells and tissues. In various Phase
II clinical trials in Japan 249 patients with brain cancer
were treated with the antibody. Overall response rate was
between 25-30%, a 9-fold increase over standard care, with
several survivors beyond 5-years post-treatment. Patients
were on a low dose regimen of 1 mg given twice a week
for a course of 24 weeks, suggesting Pritumumab to be
safe and effective in patients with brain cancer. However,
the yield from human-hybridoma was only about 1 pico-
gram per cell per day. Therefore, there is a pressing need
to produce adequate amount of GMP grade Pritumumab
in a cost effective manner. The GPEx® technology of
Catalent was adapted to develop a Pritumumab-secreting
Chinese hamster ovary (CHO) cell line. This involved con-
struction and cloning of heavy and light chain DNAs into
an expression vector and transduced into HEK 293 cells
that constitutively produce the MLV gag, pro, and pol.
The Pritumumab cell line was made by performing multi-
ple rounds of transduction (multiplicity of > 1000 retro-
vector particles/cell) of the GPEx® parental cell line
(GCHO) with retrovector made from the gene construct
developed to express the Pritumumab antibody light and
heavy chains. Five independent transductions were per-
formed: two LC and three HC. Limiting dilution method
was used to establish cloned cell lines. Top clones were
selected based on antibody titer as determined by Protein
A HPLC using a generic IgG standard. Single copies of
genes were inserted efficiently in unique locations
throughout the genome of the CHO cells to obtain
genetically stable cell line that expressed high levels of the
antibody. The selected clone represented more than a
40-fold increased production of the antibody over the
original human-hybridoma. Flow cytometry binding and
immunohistochemical analyses demonstrated comparabil-
ity between the recombinant and the hybridoma forms of
the protein. Furthermore, amino acid compositions of the
two forms are identical. Thus, high level of specific
productivity and titer of the CHO clone will allow the
therapeutic antibody program to move forward into large
and extended clinical trials of not only brain cancers but
also of other types of cancers as well.
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